With a global patient community of over 5,000, Prurigo Nodularis International is the world's only charity for anyone living with the rare, debilitating and life changing neuro-immunological skin condition, Nodular Prurigo or Prurigo Nodularis. Our vision is for a world where no one suffers with Prurigo Nodularis.

The mission of Prurigo Nodularis International is to create worldwide awareness of Prurigo Nodularis, including educating dermatologists in the impact of the disease. To drive efforts to develop diagnostic standards, care and treatment guidelines and pathways, as well as safe and effective treatments. A core part of our mission is to also create an engaged community of patients, so that no patient will ever face this disease in isolation, and to provide information and advice to help people living with Prurigo Nodularis improve the quality of their lives.

Two dedicated treatments, Dupilumab (Sanofi), which targets the IL-4 and IL-13 pathways, as well as Nemolizumab (Galderma), which targets the IL-31 pathway have been approved in the US. Dupilumab has also been approved in Europe, Scotland and other regions, but not in England. There is also a pipeline of other targeted treatments on the horizon, including JAK1 inhibitor Abrocitinib and Vixarelimab, which targets IL-31 and Oncostatin M. As long as Industry and health bodies work together to make these treatments available to this grossly underserved and neglected group of patients, for the first time the future does appear bright for our community. 

We are proud to be an Associate member of the International Alliance of Dermatology Patient Organizations - www.globalskin.org

If you are a patient or care for someone with Prurigo Nodularis join our charity's support group on Facebook:   https://www.facebook.com/groups/prurigonodularis/

Our charity website is currently under development.

Prurigo Nodularis International

Org chart

Teams

Offices